查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933368

全球犬类疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Canine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

犬类疫苗市场成长因素

预计2025年全球犬类疫苗市场规模将达到19.5亿美元，2026年将成长至20.5亿美元，到2034年将达到36.4亿美元，预测期内年复合成长率（CAGR）为7.42%。北美地区将引领市场，2025年市场占有率将达到44.85%，这主要得益于其先进的兽医基础设施、不断成长的宠物拥有率以及人们对犬类疾病预防的日益重视。宠物人性化程度的提高、可支配收入的增加以及犬隻预防保健的普及，都推动了该市场的强劲成长。

市场上的主要参与者，包括 Zoetis Services LLC、Merck & Co., Inc.、Elanco、Boehringer Ingelheim International GmbH、Virbac、Ceva、Bioveta a.s.、Indian Immunologicals Ltd.、HIPRA 和 Brilliant Bio Pharma，均提供创新的疫苗解决方案，并拓展其全球业务。例如，耶鲁大学医学院于2024年 3月研发出一种针对犬类 EGFR/HER2 蛋白的癌症疫苗，显示人们对犬类健康新型疫苗的兴趣日益浓厚。

市场动态

驱动因素：全球宠物主人数量的不断成长以及他们日益增强的对先进犬类医疗保健的投资意愿是市场成长的关键驱动因素。根据全球动物健康协会（GAHA）2022年 9月发布的报告，美国家庭饲养的宠物犬数量估计约为 8,500万隻，这表明疫苗接种具有巨大的潜力。人们对疾病预防（包括犬窝咳、莱姆病和犬流感）的认识不断提高，进一步推动了市场成长。

限制因素：犬主对疫苗接种的犹豫仍然是一个主要挑战。对疫苗安全性和副作用的担忧，以及对定期接种疫苗必要性的认识不足，导致疫苗接种率下降。根据全球疫苗免疫联盟（GAVI）2025年 1月发布的报告，4%的犬和 12%的猫仍未接种狂犬病疫苗，这反映出人们持续的犹豫和市场限制。

机会：新型联合疫苗的研发和核准将实现对多种疾病的广谱保护。2025年 7月，Eli Lilly and Company（Elanco）采用 PureFil 技术的犬流感联合疫苗 "TruCan Ultra CIV H3N2/H3N8" 获得美国农业部（USDA）的批准。这些创新将提高便利性，减少副作用，并加强疾病的全面预防。

挑战：兽医诊所就诊量下降和专业人员短缺影响市场成长。2021年至2023年间，客户就诊量下降了2.7%。此外，到2030年，全球兽医缺口约15,000人，难以满足预计的需求。这些因素阻碍了疫苗的普及，并给行业利益相关者带来了挑战。

市场趋势

更容易接种的疫苗（例如鼻内疫苗）的研发兴起。这些疫苗可以减轻宠物的压力，并使其快速产生免疫反应，而无需专业人员操作。例如，2025年3月，Zoetis Services LLC推出了Vanguard B，这是一种针对犬窝咳（博德氏菌）的鼻内疫苗，这反映了疫苗市场正朝着高效便捷的方向发展。

市场区隔分析

依技术分类：

  • 灭活疫苗因其卓越的安全性和兽医认可度高而日益普及。例如，Boehringer Ingelheim于2024年11月推出了Eurican L4，用于预防钩端螺旋体病。
  • 减毒活疫苗可提供长期免疫力，同时减少加强剂的接种次数。Merck公司的Novivac Canin1-DAPPv可同时预防多种病毒感染。
  • 重组疫苗和其他疫苗因其安全性和精准靶向性而持续成长。

依疾病类型分类：

  • 犬流感疫苗持续占据主导地位，这主要得益于病例数的增加和新核准疫苗的出现（例如，Novivac NXT犬流感H3N2疫苗于2024年6月获准）。
  • 狂犬病疫苗在全球疫苗接种计画中仍然非常重要。截至2022年6月，孟加拉已使用了225万剂狂犬病疫苗，为81.57%的流浪犬接种了疫苗。
  • 由于疾病发生率上升和预防性护理的广泛应用，莱姆病和钩端螺旋体病的发生率也在上升。

依给药途径：

  • 口服疫苗因对兽医和宠物都方便，已成为主流。Merck公司于2022年9月推出了Nobivac Intra-Trac口服BbPi疫苗。
  • 鼻腔疫苗方便快捷，可减轻压力，因此越来越受欢迎。
  • 由于政府支持的疫苗接种计划，注射疫苗仍然占据相当大的市场占有率。

依通路划分：

  • 兽医诊所凭藉其先进的设施和宠物主人的偏好，在市场中扮演着主导角色。例如，隶属于皇家兽医学院的博蒙特、塞恩斯伯里动物医院于2025年8月获得了 "犬类友善型" 认证。
  • 得益于VetRec等人工智慧辅助解决方案，兽医诊所蓬勃发展。 VetRec于2025年1月与Bond Vet达成合作。
  • 药局、药局和其他通路的成长较为温和。

区域展望

  • 北美：到2025年，北美市场规模达到8.8亿美元，其中美国凭藉其先进的医疗保健体系和政府支持，将引领市场成长。
  • 欧洲：由于宠物主人数量的不断增加，预计欧洲市场将显着成长。 在英国，28%的成年人养狗（PDSA2024）。
  • 亚太地区：预计年复合成长率最高，这主要得益于新兴市场和策略扩张（例如，Biobeta于2024年9月与印度Betina Healthcare建立合作关係）。 拉丁美洲、中东和非洲：预期成长较为温和，这主要得益于政府主导的疫苗接种计画。例如：Boehringer Ingelheim在肯亚进行的狂犬病预防活动（于2024年12月实施）。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家/地区犬类疾病概览（2025年）
  • 主要国家/地区监管状况（2025年）
  • 犬类疾病疫苗接种概览
  • 主要公司新技术应用
  • 关键趋势：併购、业务合作等

第5章 全球犬类疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依技术分类
    • 灭活疫苗
    • 减毒活疫苗
    • 重组疫苗
    • 其他
  • 市场分析、洞察与预测：依疾病类型分类
    • 犬流感
    • 莱姆病
    • 狂犬病
    • 钩端螺旋体病
    • 其他
  • 市场分析、洞察与预测：依技术分类，依给药途径分类
    • 口服
    • 注射
    • 鼻腔给药
  • 市场分析、洞察与预测：依通路分类
    • 兽医院
    • 兽药诊所
    • 药局和药局
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美犬类疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲犬类疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第8章 亚太犬类疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲犬类疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲犬类疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
  • Elanco
  • Boehringer Ingelheim International GmbH
  • Virbac
  • Merck &Co., Inc.
  • Zoetis Services LLC
  • Ceva
  • Bioveta, a.s.
  • Indian Immunologicals Ltd.
  • HIPRA
  • Brilliant Bio Pharma（India）
Product Code: FBI113897

Growth Factors of canine vaccines Market

The global canine vaccines market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.05 billion in 2026, eventually reaching USD 3.64 billion by 2034, reflecting a CAGR of 7.42% during the forecast period. North America dominated the market in 2025 with a 44.85% share, owing to advanced veterinary healthcare infrastructure, rising pet ownership, and strong awareness regarding canine disease prevention. The market is witnessing robust growth driven by the humanization of pets, increasing disposable income, and the growing adoption of preventive healthcare for dogs.

Leading companies in the market include Zoetis Services LLC, Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Ceva, Bioveta a.s., Indian Immunologicals Ltd., HIPRA, and Brilliant Bio Pharma, offering innovative vaccination solutions and expanding footprints globally. Recent research developments, such as Yale School of Medicine's cancer vaccine targeting canine EGFR/HER2 proteins in March 2024, underscore the increasing focus on novel vaccines for canine health.

Market Dynamics

Drivers: Rising pet ownership worldwide and growing willingness among pet owners to invest in advanced healthcare for dogs are primary drivers of market growth. In September 2022, the Global Animal Health Association reported around 85 million pet dogs in U.S. households, highlighting the potential for vaccine adoption. Increasing awareness about preventing diseases such as kennel cough, Lyme disease, and canine influenza further accelerates market growth.

Restraints: Vaccine hesitancy among dog owners poses a significant challenge. Concerns over vaccine safety, side effects, and the perceived necessity of routine vaccination reduce adoption rates. As per GAVI in January 2025, 4% of dogs and 12% of cats remained unvaccinated against rabies, reflecting ongoing resistance and market limitations.

Opportunities: Development and approval of novel combination vaccines offer broad-spectrum protection against multiple diseases. In July 2025, Elanco received USDA approval for TruCan Ultra CIV H3N2/H3N8, a canine influenza combination vaccine using PureFil technology. Such innovations improve convenience, reduce adverse reactions, and enhance comprehensive disease prevention.

Challenges: Decline in veterinary visits and shortage of skilled professionals affect market growth. Between 2021-2023, client visits fell by 2.7%, while a shortage of approximately 15,000 veterinarians exists globally compared to projected needs by 2030. These factors hamper vaccine adoption and present challenges for industry stakeholders.

Market Trends

The development of easy-to-administer vaccines, such as intranasal vaccines, is a growing trend. These vaccines reduce stress for pets and enable quick immune responses without specialized personnel. For instance, in March 2025, Zoetis Services LLC launched Vanguard B Intranasal vaccine, targeting Bordetella bronchiseptica (kennel cough), reflecting a shift toward efficient, user-friendly vaccination solutions.

Segmentation Analysis

By Technology:

  • Inactivated vaccines dominate due to strong safety profiles and practitioner acceptance. For example, in November 2024, Boehringer Ingelheim launched Eurican L4, protecting against leptospirosis.
  • Live attenuated vaccines offer long-lasting immunity with fewer boosters. Merck's NOBIVAC CANINE 1-DAPPv combines protection against multiple viruses.
  • Recombinant and other vaccines are growing due to safer, precise targeting.

By Disease Type:

  • Canine influenza leads due to rising cases and new approvals, e.g., NOBIVAC NXT Canine Flu H3N2 in June 2024.
  • Rabies remains significant, with global vaccination programs. In Bangladesh, 2.25 million doses were used to vaccinate 81.57% of stray dogs by June 2022.
  • Lyme disease and leptospirosis are also growing, driven by increasing disease incidence and preventive care adoption.

By Route of Administration:

  • Oral vaccines dominate due to ease of use for veterinarians and pets. Merck launched Nobivac Intra-Trac Oral BbPi in September 2022.
  • Intranasal vaccines are expanding, providing convenience and reduced stress.
  • Parenteral vaccines maintain significant market presence due to government-supported vaccination programs.

By Distribution Channel:

  • Veterinary hospitals lead due to advanced facilities and pet owner preference. For instance, Royal Veterinary College's Beaumont Sainsbury Animal Hospital earned Dog Friendly Clinic accreditation in August 2025.
  • Veterinary clinics are growing with AI-assisted solutions like VetRec partnered with Bond Vet in January 2025.
  • Pharmacies & drug stores and other channels grow moderately.

Regional Outlook

  • North America: Valued at USD 0.88 billion in 2025, led by the U.S. with advanced healthcare and government support.
  • Europe: Significant growth, driven by increasing pet ownership; in the U.K., 28% of adults own dogs (PDSA 2024).
  • Asia Pacific: Expected to witness the highest CAGR, supported by emerging markets and strategic expansions, e.g., Bioveta partnered with Vetina Healthcare in September 2024 in India.
  • Latin America & Middle East & Africa: Moderate growth, propelled by government vaccination initiatives, e.g., Boeringer Ingelheim's rabies drive in Kenya, December 2024.

Competitive Landscape

The market is semi-fragmented, with leading companies focusing on product launches, R&D, and strategic collaborations. Key players include Zoetis, Merck, Elanco, Boehringer Ingelheim, Virbac, Ceva, Bioveta, IIL, HIPRA, and Brilliant Bio Pharma. Recent industry developments include:

  • August 2025: Bioveta launched Biocan vaccines in Venezuela.
  • November 2024: Ceva established a new vaccine facility in Hungary.
  • July 2024: IIL conducted nationwide anti-rabies vaccination drives in India.

Conclusion

The global canine vaccines market is expected to grow from USD 1.95 billion in 2025 to USD 2.05 billion in 2026, reaching USD 3.64 billion by 2034 at a CAGR of 7.42%. Growth is driven by rising pet ownership, humanization of pets, preventive healthcare adoption, and government initiatives. North America dominates, while Asia Pacific exhibits the highest CAGR. Despite challenges such as vaccine hesitancy and professional shortages, innovations in combination vaccines, intranasal delivery, and strategic expansions are set to sustain market growth over the forecast period.

Segmentation By Technology

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Disease Type

  • Canine Influenza
  • Lyme Disease
  • Rabies
  • Leptospirosis
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Intranasal

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • U.S.
    • Canada
  • Europe (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Canine Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Overview of Vaccination for Canine Diseases
  • 4.4. New Technology Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Type
    • 5.2.1. Canine Influenza
    • 5.2.2. Lyme Disease
    • 5.2.3. Rabies
    • 5.2.4. Leptospirosis
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Intranasal
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Veterinary Hospitals
    • 5.4.2. Veterinary Clinics
    • 5.4.3. Pharmacies & Drug Stores
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Type
    • 6.2.1. Canine Influenza
    • 6.2.2. Lyme Disease
    • 6.2.3. Rabies
    • 6.2.4. Leptospirosis
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Intranasal
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Veterinary Hospitals
    • 6.4.2. Veterinary Clinics
    • 6.4.3. Pharmacies & Drug Stores
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Type
    • 7.2.1. Canine Influenza
    • 7.2.2. Lyme Disease
    • 7.2.3. Rabies
    • 7.2.4. Leptospirosis
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Intranasal
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Veterinary Hospitals
    • 7.4.2. Veterinary Clinics
    • 7.4.3. Pharmacies & Drug Stores
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Technology
    • 7.5.1. Inactivated
    • 7.5.2. Live Attenuated
    • 7.5.3. Recombinant
    • 7.5.4. Others
  • 7.6. Market Analysis, Insights and Forecast - By Disease Type
    • 7.6.1. Canine Influenza
    • 7.6.2. Lyme Disease
    • 7.6.3. Rabies
    • 7.6.4. Leptospirosis
    • 7.6.5. Others
  • 7.7. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.7.1. Oral
    • 7.7.2. Parenteral
    • 7.7.3. Intranasal
  • 7.8. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.8.1. Veterinary Hospitals
    • 7.8.2. Veterinary Clinics
    • 7.8.3. Pharmacies & Drug Stores
    • 7.8.4. Others
  • 7.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.9.1. Germany
    • 7.9.2. U.K.
    • 7.9.3. France
    • 7.9.4. Italy
    • 7.9.5. Spain
    • 7.9.6. Scandinavia
    • 7.9.7. Rest of Europe

8. Asia Pacific Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Type
    • 8.2.1. Canine Influenza
    • 8.2.2. Lyme Disease
    • 8.2.3. Rabies
    • 8.2.4. Leptospirosis
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Intranasal
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Veterinary Hospitals
    • 8.4.2. Veterinary Clinics
    • 8.4.3. Pharmacies & Drug Stores
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Type
    • 9.2.1. Canine Influenza
    • 9.2.2. Lyme Disease
    • 9.2.3. Rabies
    • 9.2.4. Leptospirosis
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Intranasal
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Veterinary Hospitals
    • 9.4.2. Veterinary Clinics
    • 9.4.3. Pharmacies & Drug Stores
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Type
    • 10.2.1. Canine Influenza
    • 10.2.2. Lyme Disease
    • 10.2.3. Rabies
    • 10.2.4. Leptospirosis
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Intranasal
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Veterinary Hospitals
    • 10.4.2. Veterinary Clinics
    • 10.4.3. Pharmacies & Drug Stores
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Elanco
    • 11.2.2. Boehringer Ingelheim International GmbH
    • 11.2.3. Virbac
    • 11.2.4. Merck & Co., Inc.
    • 11.2.5. Zoetis Services LLC
    • 11.2.6. Ceva
    • 11.2.7. Bioveta, a.s.
    • 11.2.8. Indian Immunologicals Ltd.
    • 11.2.9. HIPRA
    • 11.2.10. Brilliant Bio Pharma (India)

List of Tables

  • Table 1: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 2: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 3: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 8: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Canine Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 12: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 13: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 17: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 18: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 22: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 23: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 27: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 28: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Canine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Canine Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 3: Global Canine Vaccines Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 4: Global Canine Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Canine Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Canine Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 8: North America Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 9: North America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 10: North America Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 11: North America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Canine Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Canine Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 18: Europe Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 19: Europe Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 20: Europe Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 21: Europe Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 28: Asia Pacific Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 29: Asia Pacific Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 30: Asia Pacific Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 31: Asia Pacific Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 38: Latin America Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 39: Latin America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 40: Latin America Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 41: Latin America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 49: Middle East & Africa Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 50: Middle East & Africa Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 51: Middle East & Africa Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Canine Vaccines Market Share (%), By Company, 2025